Abstract
Cancers, particularly, breast cancer is one of the deadliest disease in women and requires to be treated with lowest side-effects and toxicity. Quinazolinone and Benzimidazole nucleus are privileged nucleus with reported anti-cancer activity. Hence, combined derivatives of 3-((1H-Benzo[d]imidazol-2-yl)methyl)-2-phenylquinazolin-4(3H)-one E(1-8) were prepared and tested for cytotoxicity on MCF-7 cell line. Compound E6 showed 70.74% inhibition of cell growth as compared to 86.96% inhibition by standard doxorubicin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
